Next Article in Journal
Molecular Adjuvant Ag85A Enhances Protection against Influenza A Virus in Mice Following DNA Vaccination
Next Article in Special Issue
Characterization of Clade 2.3.2.1 H5N1 Highly Pathogenic Avian Influenza Viruses Isolated from Wild Birds (Mandarin Duck and Eurasian Eagle Owl) in 2010 in Korea
Previous Article in Journal
Large Animal Models for Foamy Virus Vector Gene Therapy
Previous Article in Special Issue
Innate Immunity to H5N1 Influenza Viruses in Humans
Article Menu

Export Article

Open AccessReview
Viruses 2012, 4(12), 3589-3605; doi:10.3390/v4123589

Development of Live-Attenuated Influenza Vaccines against Outbreaks of H5N1 Influenza

1,†
,
1,†
and
1,2,*
1
Shanghai Institute of Biological Products, 1262 YanAn Road(w), 200052, Shanghai, China
2
College of Life Sciences, Hunan Normal University, Changsha Yuelushan 410081, Hunan, China
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 2 October 2012 / Revised: 14 November 2012 / Accepted: 22 November 2012 / Published: 10 December 2012
(This article belongs to the Special Issue H5N1 Influenza Virus)
View Full-Text   |   Download PDF [272 KB, uploaded 12 May 2015]

Abstract

Several global outbreaks of highly pathogenic avian influenza (HPAI) H5N1 virus have increased the urgency of developing effective and safe vaccines against H5N1. Compared with H5N1 inactivated vaccines used widely, H5N1 live-attenuated influenza vaccines (LAIVs) have advantages in vaccine efficacy, dose-saving formula, long-lasting effect, ease of administration and some cross-protective immunity. Furthermore, H5N1 LAIVs induce both humoral and cellular immune responses, especially including improved IgA production at the mucosa. The current trend of H5N1 LAIVs development is toward cold-adapted, temperature-sensitive or replication-defective vaccines, and moreover, H5N1 LAIVs plus mucosal adjuvants are promising candidates. This review provides an update on the advantages and development of H5N1 live-attenuated influenza vaccines.
Keywords: influenza; H5N1; live-attenuated influenza vaccines; cross-protection; adjuvants influenza; H5N1; live-attenuated influenza vaccines; cross-protection; adjuvants
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Zheng, D.; Yi, Y.; Chen, Z. Development of Live-Attenuated Influenza Vaccines against Outbreaks of H5N1 Influenza. Viruses 2012, 4, 3589-3605.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top